ADW-742

Details

Stereochemistry	MIXED
Molecular Formula	C28H31N5O
Molecular Weight	453.5786
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=C2C(=CN([C@H]3C[C@H](CN4CCCC4)C3)C2=NC=N1)C5=CC=CC(OCC6=CC=CC=C6)=C5

InChI

InChIKey=LSFLAQVDISHMNB-AFARHQOCSA-N

InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)/t21-,23-

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15050914 | https://www.ncbi.nlm.nih.gov/pubmed/15141010

NVP-ADW742 is a novel small weight molecular inhibitor of insulin-like growth factor-1 receptor (IGF-IR), which is investigated for treatment of different types of cancers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Insulin-like growth factor I 3 Target ID: CHEMBL3217394 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15141010	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Multiple myeloma 159 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15050914	Primary	Basic research	Unknown Approved Use Unknown
Non-small cell lung cancer 206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25081930	Primary	Basic research	Unknown Approved Use Unknown
Acute myeloid leukemia 136 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21141739	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.	2004 May	15141010
The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.	2010	21141739
The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.	2011 Jun	21455580

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

NVP-ADW742 significantly inhibits the serum-stimulated cell proliferation in a variety of tumor cell lines in dose-dependent manner, with IC50 values of 0.1-0.5 μM for the multiple myeloma (MM) cell lines, and the antitumor effects on MM cells can not be overcome by the co-culture with BMSCs. In addition, NVP-ADW742 is active against MM cell lines.

Name

Type

Language

ADW-742

Common Name

English

NVP-ADW742

Code

English

GSK-552602A

Code

English

7H-PYRROLO(2,3-D)PYRIMIDIN-4-AMINE, 5-(3-(PHENYLMETHOXY)PHENYL)-7-(TRANS-3-(1-PYRROLIDINYLMETHYL)CYCLOBUTYL)-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID70431367

Created by admin on Sat Dec 16 10:56:21 GMT 2023 , Edited by admin on Sat Dec 16 10:56:21 GMT 2023

PRIMARY

PUBCHEM

9825149

Created by admin on Sat Dec 16 10:56:21 GMT 2023 , Edited by admin on Sat Dec 16 10:56:21 GMT 2023

PRIMARY

FDA UNII

MXS2N5862L

Created by admin on Sat Dec 16 10:56:21 GMT 2023 , Edited by admin on Sat Dec 16 10:56:21 GMT 2023

PRIMARY

CAS

475488-23-4

Created by admin on Sat Dec 16 10:56:21 GMT 2023 , Edited by admin on Sat Dec 16 10:56:21 GMT 2023

PRIMARY

ACTIVE MOIETY


					MXS2N5862L

ADW-742

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15050914 | https://www.ncbi.nlm.nih.gov/pubmed/15141010

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

PubMed

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15050914 | https://www.ncbi.nlm.nih.gov/pubmed/15141010